{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:14:53Z","timestamp":1790817293798,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Victorian Government Department of Health and Human Services"},{"name":"Victorian Medical Research Acceleration Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Statins, renin\u2013angiotensin system inhibitors (RASIs) and beta-blockers are guideline-recommended cardiovascular medications post-myocardial infarction (MI) for secondary prevention, but evidence for people with dementia is scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between post-MI cardiovascular medication use and the risk of cardiovascular outcomes and mortality, focusing on people with dementia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Large retrospective cohort study using data from Australia, Finland, Taiwan, the UK and the USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects<\/jats:title>\n                    <jats:p>People with and without dementia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seven exposure groups were assigned using one or combinations of the three guideline-recommended medication classes\u2014(i) statin, RASI and beta-blocker, (ii) statin and beta-blocker, (iii) statin and RASI, (iv) RASI and beta-blocker, (v) statin only, (vi) beta-blocker only and (vii) RASI only, based on medication records during a 60-day landmark period post-MI. Recurrent MI, major adverse cardiovascular event (MACE) and all-cause mortality were evaluated as outcomes. Jurisdiction-specific results were pooled together using meta-analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 28\u2009122 people with dementia and 260\u2009360 people without dementia were included. Among people with dementia, using any single or two medications carried a similar risk of recurrent MI and MACE as using all three guideline-recommended medications, except that using RASI and a beta-blocker without a statin was associated with a lower risk of recurrent MI (HR 0.85; 95% CI, 0.75\u20130.96). Using a statin and RASI without beta-blockers resulted in similar all-cause mortality to using all three (HR 1.16; 95% CI, 0.97\u20131.39), while all the remaining single- or dual-medication regimens were associated with higher risks of all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For people with dementia, using one or two guideline-recommended medications appeared sufficient to protect against recurrent MI and MACE. Beta-blockers may not provide additional survival benefits over statins and RASIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ageing\/afag220","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:43:45Z","timestamp":1783424625000},"source":"Crossref","is-referenced-by-count":1,"title":["Secondary prevention of myocardial infarction in people with dementia: a multi-jurisdictional retrospective cohort study in Asia, Europe and the USA"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-9441","authenticated-orcid":false,"given":"Jenni","family":"Ilom\u00e4ki","sequence":"first","affiliation":[{"name":"Centre for Medicine Use and Safety, Monash University , 381 Royal Parade, Parkville, Victoria 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-729X","authenticated-orcid":false,"given":"George S Q","family":"Tan","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Monash University , 381 Royal Parade, Parkville, Victoria 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen Simon","family":"Qin","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Monash University , 381 Royal Parade, Parkville, Victoria 3052 ,","place":["Australia"]},{"name":"Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Region ,","place":["China"]},{"name":"Laboratory of Data Discovery for Health (D24H) , Hong Kong Science Park, Hong Kong Special Administrative Region ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maija","family":"Tolppanen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Eastern Finland , Kuopio ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Lin","sequence":"additional","affiliation":[{"name":"Finland Pure-Fountain Ltd , Hammaslahti ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian Tian","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shenzhen Second People\u2019s Hospital , Shenzhen, Guangdong ,","place":["China"]},{"name":"School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University , Tainan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Hsing-Chun Hsieh","sequence":"additional","affiliation":[{"name":"Population Health Data Centre, National Cheng Kung University , Tainan ,","place":["Taiwan"]},{"name":"UCL School of Pharmacy , University College London, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella Jung-Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Monash University , 381 Royal Parade, Parkville, Victoria 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Marquina","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Monash University , 381 Royal Parade, Parkville, Victoria 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Chia-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Population Health Data Centre, National Cheng Kung University , Tainan ,","place":["Taiwan"]},{"name":"UCL School of Pharmacy , University College London, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[{"name":"UCL School of Pharmacy , University College London, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Wood","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Monash University , 381 Royal Parade, Parkville, Victoria 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-0014","authenticated-orcid":false,"given":"Ian C K","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Region ,","place":["China"]},{"name":"Laboratory of Data Discovery for Health (D24H) , Hong Kong Science Park, Hong Kong Special Administrative Region ,","place":["China"]},{"name":"Aston Centre of Excellence in Pharmacotherapy Optimisation and Pharmacoepidemiology Research School of Pharmacy, Aston University , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Fang","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Hartikainen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Eastern Finland , Kuopio ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Annis","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui-Kai","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Hong Kong, Hong Kong Special Administrative Region ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-2767","authenticated-orcid":false,"given":"J Simon","family":"Bell","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Monash University , 381 Royal Parade, Parkville, Victoria 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"2026080714073846200_ref1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019","volume":"7","author":"Nichols","year":"2022","journal-title":"Lancet Public Health"},{"key":"2026080714073846200_ref2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"Nichols","year":"2019","journal-title":"Lancet Neurol"},{"key":"2026080714073846200_ref3","doi-asserted-by":"publisher","first-page":"e0175475","DOI":"10.1371\/journal.pone.0175475","article-title":"Comorbidity and dementia: a nationwide survey in Taiwan","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"key":"2026080714073846200_ref4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijcard.2013.10.065","article-title":"Incident ischaemic heart disease in persons with Alzheimer\u2019s disease in a Finnish nationwide exposure-matched cohort","volume":"170","author":"Tolppanen","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026080714073846200_ref5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/JAD-150259","article-title":"30-day mortality after cardiovascular events in persons with or without Alzheimer\u2019s disease","volume":"48","author":"Heiskanen","year":"2015","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2026080714073846200_ref6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1471-244X-14-84","article-title":"Comorbidity of dementia: a cross-sectional study of primary care older patients","volume":"14","author":"Poblador-Plou","year":"2014","journal-title":"BMC Psychiatry"},{"key":"2026080714073846200_ref7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2318-14-10","article-title":"A claims data-based comparison of comorbidity in individuals with and without dementia","volume":"14","author":"Bauer","year":"2014","journal-title":"BMC Geriatr"},{"key":"2026080714073846200_ref8","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.3399\/bjgp13X663046","article-title":"Under-provision of medical care for vascular diseases for people with dementia in primary care: a cross-sectional review","volume":"63","author":"Connolly","year":"2013","journal-title":"Br J Gen Pract"},{"key":"2026080714073846200_ref9","doi-asserted-by":"publisher","first-page":"e897671","DOI":"10.1155\/2014\/897671","article-title":"Effect of dementia on the use of drugs for secondary prevention of ischemic heart disease","volume":"2014","author":"Fowler","year":"2014","journal-title":"J Aging Res"},{"key":"2026080714073846200_ref10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jamda.2013.12.085","article-title":"Prevalence and correlates of cardiovascular medication use among nursing home residents with ischemic heart disease: results from the SHELTER study","volume":"15","author":"Foebel","year":"2014","journal-title":"J Am Med Dir Assoc"},{"key":"2026080714073846200_ref11","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"2026080714073846200_ref12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Armitage","year":"2019","journal-title":"Lancet"},{"key":"2026080714073846200_ref13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jacl.2020.11.008","article-title":"The changing pattern of statin use in people with dementia: a population-based study","volume":"15","author":"Picton","year":"2021","journal-title":"J Clin Lipidol"},{"key":"2026080714073846200_ref14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijcard.2019.09.036","article-title":"Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer\u2019s disease","volume":"300","author":"Vu","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026080714073846200_ref15","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s13063-019-3603-1","article-title":"Protection by exclusion? The (lack of) inclusion of adults who lack capacity to consent to research in clinical trials in the UK","volume":"20","author":"Shepherd","year":"2019","journal-title":"Trials"},{"key":"2026080714073846200_ref16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.hlc.2016.06.789","article-title":"National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016","volume":"25","author":"Chew","year":"2016","journal-title":"Heart Lung Circ"},{"key":"2026080714073846200_ref17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080714073846200_ref18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jfma.2018.06.002","article-title":"2018 guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome","volume":"117","author":"Li","year":"2018","journal-title":"J Formos Med Assoc"},{"key":"2026080714073846200_ref19","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3233\/JAD-190503","article-title":"Beta-blockers for the secondary prevention of myocardial infarction in people with dementia: a systematic review","volume":"71","author":"Lanham","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"2026080714073846200_ref20","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s40263-020-00742-4","article-title":"Application of healthcare \u2018big data\u2019 in CNS drug research: the example of the neurological and mental health global epidemiology network (NeuroGEN)","volume":"34","author":"Ilom\u00e4ki","year":"2020","journal-title":"CNS Drugs"},{"key":"2026080714073846200_ref21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1161\/CIRCOUTCOMES.111.964700","article-title":"Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010","volume":"5","author":"Smolina","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026080714073846200_ref22","doi-asserted-by":"publisher","first-page":"ehaf784.1935","DOI":"10.1093\/eurheartj\/ehaf784.1935","article-title":"Recurrent compared to first-time myocardial infarction is associated with worse long-term outcomes","volume":"46","author":"Christensen","year":"2025","journal-title":"Eur Heart J"},{"key":"2026080714073846200_ref23","doi-asserted-by":"publisher","first-page":"e012100","DOI":"10.1136\/bmjopen-2016-012100","article-title":"Cohort profile: the Finnish medication and Alzheimer\u2019s disease (MEDALZ) study","volume":"6","author":"Tolppanen","year":"2016","journal-title":"BMJ Open"},{"key":"2026080714073846200_ref24","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a hospital frailty risk score focusing on older people in acute care settings using electronic hospital records: an observational study","volume":"391","author":"Gilbert","year":"2018","journal-title":"Lancet"},{"key":"2026080714073846200_ref25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/1060028014568447","article-title":"Use of statins and antihypertensive medications in relation to risk of long-standing persistent atrial fibrillation","volume":"49","author":"Thacker","year":"2015","journal-title":"Ann Pharmacother"},{"key":"2026080714073846200_ref26","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.2169\/internalmedicine.8932-21","article-title":"A propensity score matched analysis of statin effects on major adverse cardiac events after percutaneous coronary intervention in patients over 75 years old","volume":"61","author":"Horikoshi","year":"2022","journal-title":"Intern Med"},{"key":"2026080714073846200_ref27","doi-asserted-by":"publisher","first-page":"e025813","DOI":"10.1161\/JAHA.122.025813","article-title":"Intensity of and adherence to lipid-lowering therapy as predictors of major adverse cardiovascular outcomes in patients with coronary heart disease","volume":"11","author":"Mazhar","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026080714073846200_ref28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"key":"2026080714073846200_ref29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the e-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026080714073846200_ref30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2026080714073846200_ref31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jamainternmed.2016.7701","article-title":"Impact of beta blockers on functional outcomes, death, and rehospitalization in older nursing home residents following acute myocardial infarction","volume":"177","author":"Steinman","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2026080714073846200_ref32","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jgs.16342","article-title":"Benefits and harms of statins in people with dementia: a systematic review and meta-analysis","volume":"68","author":"Davis","year":"2020","journal-title":"J Am Geriatr Soc"},{"key":"2026080714073846200_ref33","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00228-022-03320-3","article-title":"Statin discontinuation in persons with and without Alzheimer\u2019s disease","volume":"78","author":"Vu","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"2026080714073846200_ref34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3233\/JAD-180219","article-title":"Prevalence, safety, and effectiveness of oral anticoagulant use in people with and without dementia or cognitive impairment: a systematic review and meta-analysis","volume":"65","author":"Fanning","year":"2018","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2026080714073846200_ref35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/jgs.14573","article-title":"Continued use of warfarin in veterans with atrial fibrillation after dementia diagnosis","volume":"65","author":"Orkaby","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"2026080714073846200_ref36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s12877-022-03144-x","article-title":"Prevalence of oral anticoagulant use among people with and without Alzheimer\u2019s disease","volume":"22","author":"Ali Babar","year":"2022","journal-title":"BMC Geriatr"},{"key":"2026080714073846200_ref37","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3233\/JAD-190094","article-title":"Trends and predictors of oral anticoagulant use in people with Alzheimer\u2019s disease and the general population in Australia","volume":"70","author":"Ilom\u00e4ki","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"2026080714073846200_ref38","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S2468-2667(17)30031-2","article-title":"Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study","volume":"2","author":"Donegan","year":"2017","journal-title":"Lancet Public Health"},{"key":"2026080714073846200_ref39","doi-asserted-by":"publisher","first-page":"k1315","DOI":"10.1136\/bmj.k1315","article-title":"Anticholinergic drugs and risk of dementia: case-control study","author":"Richardson","year":"2018","journal-title":"BMJ"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/55\/8\/afag220\/70535551\/afag220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/55\/8\/afag220\/70535551\/afag220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:07:42Z","timestamp":1786126062000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ageing\/article\/doi\/10.1093\/ageing\/afag220\/8754497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afag220","relation":{},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"value":"0002-0729","type":"print"},{"value":"1468-2834","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]},"article-number":"afag220"}}